Researchers say sleeping blood pressure
(BP) may be novel target for diabetes prevention. According to new
research, taking hypertension medication before bed rather than in
the morning not only lowers nighttime blood pressure but also
protects against new-onset diabetes.
Lead researcher, Ramón Hermida, PhD,
of the University of Vigo, Spain stated that sleeping BP — but not
daytime or 48-hour ambulatory BP — was found to be a significant
predictor of new-onset diabetes and may be a novel target for
prevention.
Medications that block the
renin-angiotensin-aldosterone system (RAAS), such as angiotensin
receptor blockers (ARBs) and ACE inhibitors, had the strongest
antidiabetic effect. “Activation of the
renin-angiotensin-aldosterone system (RAAS) and consequent elevations
of angiotensin II and aldosterone contributes to increased hepatic
glucose release and decreased insulin sensitivity,” the
investigators wrote. They added that the RAAS follows a circadian
rhythm, becoming active during sleep.
Accordingly, in addition to
BP-lowering, RAAS blockade might also serve as an effective strategy
to control impaired glucose and insulin tolerance.
The prospective study included more
than 2,000 hypertensive patients enrolled in the Ambulatory Blood
Pressure Monitoring for Prediction of Cardiovascular Events (MAPEC)
study. Their average age was 53, and they were roughly half men and
half women. Participants were randomized to a bedtime group that
took the entire daily dose of one or more of their hypertension
medications before bed, and a daytime group that took all their
hypertension medications upon waking.
Blood pressure was assessed annually in
both groups by daytime clinic measurement and by 48-hour ambulatory
blood pressure (ABP) monitoring. Blinded investigators assessed the
development of new-onset diabetes. During a median follow-up of 5.9
years, 171 study participants developed diabetes. Incidence of
new-onset diabetes was significantly lower in the bedtime group
(4.8%) versus the daytime group (12%) (P less than 0.001).
After adjusting for factors, including
fasting glucose, waist circumference, and chronic kidney disease, the
investigators found the bedtime group was 57% less likely to develop
diabetes (P less than 0.001).
The daytime BP measured in the clinic
or by ambulatory monitoring did not predict new-onset diabetes.
The research team concluded that
“lowering asleep BP, a novel therapeutic target requiring ABP
evaluation, could be a significant method for reducing new-onset
diabetes risk.”
In summary, ambulatory BP monitoring is
needed not only for proper diagnosis of hypertension and
quantification of cardiovascular risk, but also, within this context,
for evaluation of the individual’s risk of developing diabetes,
rendering ambulatory BP a cost-effective technique that should be
recommended in all adults.
In conclusion, changing the time of
ingestion of hypertension medications, a zero-cost intervention, has
been shown to reduce cardiovascular morbidity and mortality and, be
in keeping with the new findings.
This study reinforces the importance of
taking hypertension medication at night, particularly drugs that have
an anti-renin effect — ACE inhibitors, ARBs, and mineralocorticoid
receptor antagonists.
It is a known fact that dosing at night
is preferable for many drugs, in particular drugs that modulate the
RAAS. Hypertension specialists know this. But the average person in
the field may not be aware of this.
Read the full article here.
No comments:
Post a Comment